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Abstract
The ability of pneumococcal conjugate vaccine (PCV) to decrease transmission by blocking the 
acquisition of colonization has been attributed to herd immunity. We describe the role of mucosal 
IgG to capsular polysaccharide (CPS) in mediating protection from carriage, translating our 
findings from a murine model to humans. We used a flow-cytometric assay to quantify antibody-
mediated agglutination demonstrating that hyperimmune sera generated against an unencapsulated 
mutant was poorly agglutinating. Passive immunization with this antiserum was ineffective to 
block acquisition of colonization compared to agglutinating antisera raised against the 
encapsulated parent strain. In the human challenge model samples were collected from PCV and 
control vaccinated adults. In PCV-vaccinated subjects IgG levels to CPS were increased in serum 
and nasal wash (NW). IgG to the inoculated strain CPS dropped in NW samples after inoculation 
suggesting its sequestration by colonizing pneumococci. In post-vaccination NW samples 
pneumococci were heavily agglutinated compared to pre-vaccination samples in subjects protected 
against carriage. Our results indicate that pneumococcal agglutination mediated by CPS specific 
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antibodies is a key mechanism of protection against acquisition of carriage. Capsule may be the 
only vaccine target that can elicit strong agglutinating antibody responses, leading to protection 
against carriage acquisition and generation of herd immunity.
INTRODUCTION
The human nasal mucosa forms the first line of defence against respiratory pathogens. Some 
of these pathogens such as Streptococcus pneumoniae (the pneumococcus) can 
asymptomatically colonise the upper respiratory tract (the carrier state). 1 Although most 
episodes of pneumococcal carriage do not result in disease, the organism may gain access to 
normally sterile sites in its human host from its niche on the mucosal surfaces of the upper 
airways. 2 Mucosal immune responses, therefore, play a critical role in the defence against 
pneumococcal infections as they dictate the outcome of host-pathogen interactions at the 
mucosa.
Murine models have demonstrated that once carriage is established the generation of 
mucosal antibodies is ineffective at clearing the organism. 3, 4 However, mucosal antibody, if 
present before stable colonization occurs, may block acquisition through its agglutinating 
activity, a mechanism dependent on its multi-valency and independent of Fc, complement 
and opsonophagocytosis. 5 The ability of agglutinating antibody to inhibit the establishment 
of mucosal colonization could be attributed to more efficient mucociliary clearance of larger 
particles and the requirement for a larger colonizing dose. Since pneumococci enzymatically 
inactivate the agglutinating activity of human IgA1, the most abundant form of 
immunoglobulin on the airway surface, the prevention of colonization requires sufficient 
mucosal levels of other subclasses such as IgG. 6 The ability of the pneumococcus to target 
and evade human-specific components of humoral immunity emphasizes the need to 
examine the mechanisms of mucosal protection in the natural host.
The serotype-specific success of the pneumococcal conjugate vaccine (PCV) in reducing 
rates of carriage of vaccine-type strains in immunized populations indicates that anti-
capsular antibodies reduce transmission by blocking the acquisition of colonization.7 PCV 
vaccination induces high levels of serum IgG that access the mucosal surface in vaccinated 
children, however, the exact mechanism by which this vaccine mediates mucosal protection 
has not been described. 8 We recently reported that PCV conferred a 78% reduction in 
carriage acquisition compared to a control group following inoculation of adults with live 
type 6B pneumococci in an experimental human pneumococcal carriage (EHPC) study. 9
In this report, we utilize a flow cytometric assay to quantify the agglutinating effect of anti-
pneumococcal antibodies. This assay allowed us to examine the role of pneumococcal 
surface antigens and demonstrate the importance of antibodies to its immunodominant 
antigen, capsular polysaccharide (CPS), in eliciting agglutinating IgG that protects from the 
acquisition of colonization. This assay was then used to investigate the role of mucosal 
antibodies to capsule antigens in mediating agglutination and protection against acquisition 
of pneumococcal carriage in the natural host in an EHPC study of PCV.
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RESULTS
A flow cytometric assay to quantify pneumococcal agglutination by antibody
To quantify bacterial agglutination, we developed and optimized a flow cytometric assay. 
After a brief incubation of pneumococci with type-specific antibody, there was a dose-
dependent increase in the shift in forward scatter (FSC) (Fig. 1A). At higher concentrations, 
there was also an increase in side scatter (SSC). Samples were then analysed under similar 
conditions using an Amnis Imaging Flow Cytometer to visualize the individual events 
detected by the laser. The change in particle size, as detected by shift in FSC, and 
complexity, as detected by shift in SSC, correlated with a progressive bridging of particles to 
form longer chains (threading reaction) by antibody. 10 As the concentration of antibody was 
increased further these formed into aggregates of increasing size. Furthermore, divalent 
F(ab’)2 fragments generated from this antibody5 caused a similar shift in FSC and 
corresponding visual agglutination of bacteria, unlike an equivalent concentration of 
monovalent Fab fragments (Fig. 1B). Together these data confirm that flow cytometry is a 
sensitive method to detect and quantify bacterial agglutination by antibody.
Capsule is the major agglutinating antigen and leads to enhanced protection
Using this flow cytometric assay for agglutination, we examined which pneumococcal 
surface antigens could generate agglutinating antibodies. We raised hyperimmune rabbit 
anti-sera against whole-cell heat-killed P1121, a type 23F isolate (P2109, encapsulated 
strain), and a genetically-modified mutant of P1121 lacking the capsular antigen 
(unencapsulated strain). Immunisation with these strains led to a robust antibody response, 
and the ELISA IgG titers to whole bacteria were not significantly different whether 
antiserum was raised against the encapsulated or unencapsulated strain (Fig. 2A). As 
expected, only antiserum raised to the encapsulated strain contained antibody recognising 
purified type 23 CPS by ELISA (Fig. 2B). Using these rabbit antisera, we then compared 
agglutination using the flow cytometric assay and found that only antiserum raised against 
the encapsulated strain was able to agglutinate the wild-type encapsulated bacteria (Fig. 2C). 
In contrast, the antiserum raised against the isogenic strain lacking the capsular antigen 
showed minimal agglutination of either the encapsulated or the unencapsulated strains. This 
suggests that while the array of non-capsular antigens underlying the capsule is able to 
induce a strong immune response, antibody to these antigens is relatively poorly 
agglutinating. Therefore, capsular antigens may be the only antigens that can efficiently 
promote agglutination. To confirm the requirement for the capsular antigen in agglutination, 
isogenic strains in which the capsule-type was genetically switched were compared using 
the flow cytometric assay. Pneumococcal agglutination required type-specific antibody 
regardless of genetic background (Fig. 2D). There did not appear to be a significant 
contribution of other constituents determined by genetic background to agglutination. The 
agglutinating ability of antibodies has been shown to protect from the acquisition of 
colonization. 5 We used a murine model of colonization to compare the antisera raised to the 
isogenic encapsulated and unencapsulated strains. After intranasal challenge with strain 
P1121, mice that had been passively immunized with antisera against the encapsulated strain 
were more protected from colonization compared to mice immunized with the antisera 
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against its unencapsulated mutant (Fig. 2E). This confirmed that the agglutinating ability of 
anti-capsular antibody is important for limiting colonization acquisition.
Anti-PS IgG-mediated protection against experimental carriage in PCV vaccinated subjects
To investigate whether anti-capsular antibody generated through vaccination with PCV 
could mediate protection against carriage acquisition through agglutination, we studied 
samples from the PCV/EHPC study in which PCV vaccinated subjects had 78% protection 
against carriage acquisition with 6B strain.9 IgG levels to the vaccine-included CPS 6B and 
23F were measured at Pre-V, Post-V and 21 days after pneumococcal inoculation in sera 
samples as well as at day 2 after inoculation in nasal wash (NW) samples (Supplementary 
Fig. 1).
As expected, PCV-vaccinated subjects had increased IgG levels to both capsule-types in 
serum Post-V compared to Pre-V levels (Fig. 3). Only 5 out of 48 subjects vaccinated with 
PCV became colonized following pneumococcal inoculation (carriage+). In carriage+ 
subjects, only a modest 2.6-fold increase in levels of IgG to 6B CPS was observed in serum 
following vaccination, considerably less than the 8.4-fold increase observed in subjects 
protected from carriage (carriage−) (Fig. 3A). A similar pattern was observed in NW 
samples (Fig. 3C). Interestingly, amongst carriage+ subjects, only one volunteer had 
increased IgG levels in NW Post-V. Pneumococcus was recovered from the nasopharynx of 
this volunteer at a very low density and at only one time point.
While IgG levels remained unaltered following pneumococcal inoculation in sera (Fig 3A 
and 3B), levels of IgG to the CPS of inoculated 6B strain significantly dropped in NW 2 
days after inoculation compared to levels prior to inoculation (Fig. 3C). No decrease was 
observed in levels of IgG to 23F CPS following pneumococcal inoculation with the 6B strain 
(Fig. 3D). These data suggest that capsule-specific antibody is sequestered in the nasal 
lumen following pneumococcal inoculation that could play a role in protection against 
carriage acquisition.
Carriage boosts pre-existing levels of IgG to CPS of inoculated strain
We have previously shown that exposure to pneumococci following intranasal inoculation 
boosted pre-existing levels of CPS IgG to 6B CPS in serum only for subjects who developed 
carriage.11 In this study we confirmed this observation in a larger group of participants and 
further observed that levels are also increased in NW following carriage (Fig. 3E and 3G). 
As expected, we observed no increase in levels of IgG to both capsular-types in the control 
group following vaccination with the Hep-A vaccine (Fig. 3 E-H) and no alteration in levels 
of IgG to the 23F CPS following inoculation with the 6B strain (Fig. 3F and 3H).
Correlation between levels of IgG to 6B CPS in serum and nasal wash samples
There was a positive correlation between levels of IgG to 6B CPS in serum and NW in PCV 
vaccinated subjects (Fig. 4), which indicates that systemic antibodies elicited by vaccination 
transudate to the nasal lumen. A similar correlation was observed between levels of systemic 
and nasal IgG in carriage+ subjects 21 days following carriage (Supplementary Fig. 2).
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IgG mediates bacterial agglutination in the nasal mucosa in PCV vaccinated subjects
We then examined whether IgG present in NW from PCV vaccinated subjects could promote 
bacterial agglutination. Using concentrated NW samples incubated with the 6B strain, we 
observed increased pneumococcal agglutination in Post-V samples compared to Pre-V 
samples (19.4 ±15.1 vs 12.4 ± 7.8). This increased antibody-mediated agglutination was 
observed only in volunteers protected from carriage acquisition (carriage−) (Fig. 5A). Levels 
of IgG to 6B CPS correlated with levels of agglutination observed in NW from carriage− 
(Fig. 5B; closed circles) but not carriage+ subjects (Fig. 5B; open circles).
We also examined agglutination capacity of IgG present in NW from Hep-A vaccinated 
control subjects prior to pneumococcal inoculation, to investigate whether agglutination 
capacity of naturally acquired IgG was associated with protection against carriage 
acquisition. No difference was observed between carriage− and carriage+ groups (Fig. 6A) 
and agglutination levels were low in both groups, which could be due to the low levels of 
IgG to 6B CPS present in these samples (Fig. 3G). No correlation was observed between 
IgG to 6B CPS present in NW and agglutination levels in either carriage− or carriage+ 
groups (Fig. 6B and 6C).
DISCUSSION
Our study provides insight into the mechanisms of mucosal defence against pathogens and 
how humoral immunity generated through vaccination contributes to protection. We 
demonstrate that the ability of antibody to block the establishment of colonization in the 
human host, the first step in pathogenesis of disease caused by S. pneumoniae, correlates 
with its agglutinating activity. 1, 12 Our focus was on IgG because it is generated in high 
concentrations in response to systemic immunization and has been shown to be sufficient to 
promote agglutination on the mucosal surface.5 We have measured both IgA1 and IgA2 in 
NW samples pre- and post-inoculation with pneumococcus and IgA1 was the dominant IgA 
subclass in the nasal mucosa (data not shown). Secretory antibodies are unlikely to be 
sufficient factor in agglutination due to the activity of pneumococcal IgA1 protease and the 
moderated increase of S-IgM levels post-vaccination.13, 14
This study required a sensitive method to quantify agglutination. Through use of technology 
that simultaneously provides images of individual events detected during flow cytometric 
analysis, we confirmed that flow characteristics were a sensitive and specific measure of the 
magnitude of antibody-induced agglutination. By comparing hyperimmune sera generated to 
isogenic strains differing only in expression of CPS amount and type, we showed that type-
specific antibody to CPS was necessary for agglutination. Data from the EHPC study with 
parenterally-administered PCV confirmed that anti-CPS IgG is protective from colonization 
and is sufficient to generate mucosal agglutinating activity. This observation provided 
mechanistic understanding of the effectiveness of CPS-based immunity in reducing rates of 
mucosal infection and conferring herd immunity in the population15. This same mechanism 
may be applicable to vaccines using the CPSs of other encapsulated pathogens that also 
impact mucosal colonization.16, 17 In our study using whole pneumococci, only antibody to 
CPS was agglutinating. Yet, it remains possible that a sufficient amount of antibody to 
another pneumococcal target or combination of targets could elicit agglutinating antibody. It 
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also remains possible, however, that CPS is the only pneumococcal target that may elicit 
agglutination by specific antibodies. CPS is a highly abundant surface antigen and capable 
of inducing high levels of immunoglobulin, particularly when conjugated to an 
immunogenic protein carrier. Additionally, CPS variably shields underlying surface antigens 
from recognition by antibody. However, even when equivalent amounts of antibody to whole 
pneumococci were compared, only sera containing antibody to type-specific CPS elicited 
detectable agglutination. Thus, the amount of bound antibody does not appear to be the only 
factor contributing to agglutination.
Using an experimental model of human pneumococcal carriage, we previously demonstrated 
that PCV is highly protective against 6B pneumococcal carriage acquisition, conferring a 
78% reduction in carriage acquisition.9 We now document that in protected adults, PCV 
induced high levels of IgG to 6B CPS at the nasal mucosa. Nasal washes collected post PCV 
vaccination had increased pneumococcal agglutination capacity compared to nasal wash 
samples collected before vaccination. Agglutination levels correlated with levels of IgG to 
6B CPS. Interestingly, while levels of IgG to 23F CPS were unaltered in nasal wash after 
inoculation, levels of IgG to 6B CPS were reduced – this suggests that antibodies to 6B CPS 
were sequestered onto the bacterial surface in the nasal lumen following inoculation. Thus, 
the immunogenicity of PCV is sufficient to generate levels of IgG that reach the mucosal 
surface in amounts that bind to and agglutinate pneumococci when the host is exposed to the 
pathogen. Optimal protection may require the presence of agglutinating levels of antibody at 
the time of first exposure on the mucosal surface potentially explaining why the vaccine may 
prevent new carriage events but does not impact pre-existing colonization. It remains 
unknown whether humoral immunity generated by natural carriage generates protective 
agglutinating antibody that affects subsequent type-specific exposure to the organism. In 
previous EHPC studies we have shown that pneumococcal carriage protects healthy adults 
against subsequent carriage following re-exposure to the homologous strain11 but not against 
acquisition of a heterologous strain type.18 More recently we have shown that high baseline 
levels of circulating memory B-cells secreting IgG to CPS, but not to protein antigens, were 
associated with protection against carriage acquisition in unvaccinated adults.18 Taken 
together our findings suggest that anti-capsular IgG-mediated agglutination is a key 
mechanism of protection against pneumococcal carriage acquisition, in particular in subjects 
with high antibody titers, such as those vaccinated with PCV.
Our findings have several implications for vaccine development. Current anti-pneumococcal 
vaccines are limited by a serotype-specific approach and the diversity of pneumococcal 
types. Most of the effectiveness of pneumococcal vaccines, however, results from their 
ability to reduce transmission by decreasing rates of colonization in the population.15 Thus, 
for any novel vaccine containing more conserved target(s) to be as effective it would need to 
similarly impact carriage, and our study suggests that this would require the generation of 
agglutinating antibody on the mucosal surface of the upper airways.
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MATERIALS AND METHODS
Pneumococcal strains
The strains used in this study include BHN418 (type 6B, used for human experimental 
carriage studies19, P1121 (type 23F, isolated from the nasopharynx in a human experimental 
carriage study20 , P2109 (P1121Δcps)20 intermediate mutant in creating 2140), P1542 (type 
4 isolate, 21, 22, P1690 (P1542 background with type 23F capsule23, P2140 (P1121 
background with type 4 capsule.23 A GFP-expressing version of P1121 was used to 
differentiate bacteria from calibration beads in experiments with the Amnis ImageStreamX 
Imaging Flow Cytometer. All strains were grown in tryptic soy broth at 37°C, and were 
passaged intranasally in mice prior to preparation of frozen stocks, with exception of the 6B 
strain which were grown in Vegetone broth (for human inoculation) at 37°C 5% CO2 until 
early log phase and frozen.
Pneumococcal Conjugate Vaccine Experimental Human Pneumococcal Carriage (PCV/ 
EHPC) study
The PCV/EHPC study was conducted in 2012 and detailed methods for recruitment, 
nasopharyngeal pneumococcal inoculation and carriage detection as well as study design 
and study outcomes have been previously described.9 Ethical approval was obtained from 
the National Health Service (NHS) Research Ethics Committee (REC) (12/NW/0873). This 
study was co-sponsored by the Royal Liverpool and Broadgreen University Hospitals Trust 
and the Liverpool School of Tropical Medicine.
Briefly, 96 healthy adults aged 18–50 years were enrolled with informed consent and 
randomised to receive a single dose of either PCV-13 (Prevnar, Pfizer) or Hep-A vaccine as a 
control group (Avaxim, Sanofi Pasteur MSD). 4-5 weeks following vaccination subjects 
were intra-nasally inoculated with live 6B pneumococcus (BHN418) (80,000 CFUs per 
nostril).24 Sera samples were collected before vaccination (Pre-V), after vaccination/prior to 
pneumococcal inoculation (Post-V) and 21 days after pneumococcal inoculation. Nasal wash 
(NW) samples were collected at the same time points and also at days 2, 7 and 14 following 
pneumococcal inoculation (Supplementary Fig 1).
Antibody level measurements
IgG levels to Capsular polysaccharides 6B and 23F were measured using the WHO 
standardised ELISA method, as previously described. 7, 25, 26 Whole-cell ELISA was 
performed, as previously described 21 with the following minor modifications; serum was 
diluted in doubling concentrations, and the standardized development time altered to 30 
mins. Antigen-specific antibodies were detected by goat anti-mouse IgG (1/4,000; heavy and 
light chains)-alkaline phosphatase (Sigma). Purified type 23 CPS (ATCC) was fixed to 
Immulon 1B plates at a final concentration of 5 μg/ml in saline at 4°C and used in an ELISA 
to quantify anti-capsular antibody in rabbit serum, as described previously.5
Hep-A specific IgG purification from human serum samples
Hep-A IgG was purified from 7 pooled sera samples taken from Hep-A-vaccinated subjects 
to be used as a negative control in agglutination assays. Protein specific IgG purification was 
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done in two-stages following the manufacturer's instructions and as previously published by 
our group. 27 First, total IgG was purifed by Sepharose protein G (GE Healthcare) and then 
anti-Hep-A IgG by CNBr activated Sepharose (300mg CNBr activated Sepharose gel 
coupled with 1mg Hep-A purified protein, Abcam ab49011). Dot blot and ELISA were 
performed to confirm anti-Hep-A IgG purification and concentration (data not shown).
Rabbit antisera
Fixed and heat-killed whole-cell bacteria were prepared as follows; P1121 and P2109 were 
grown at 37°C to mid-log-phase, fixed in 1% paraformaldehyde for 1 hour at room 
temperature, washed in PBS, incubated for 30 minutes at 65°C, and stored at 4°C.28 Antisera 
were generated in rabbits by Cocalico Biological (Reamstown, PA). 50 μg bacterial protein 
(approximately 2 × 108 CFU) was injected intravenously three times weekly for 16 weeks 
the point at which titers no longer increased, as previously described.29 Fab and F(ab’)2 
fragments were generated from type-specific rabbit IgG as previous described.5
Agglutination assay
Pneumococci were grown to mid-log-phase and stored at −80°C in glycerol. On the day of 
the experiment cells were thawed and washed with PBS. For agglutination assays with 
human NW samples 3 μl of 105 bacteria was incubated with 47 μl of concentrated NW 
supernatant (1ml of NW concentrated to 100 μl using vacuum concentrator RVC2-18) and 
samples were vortexed lightly. Antiserum to group 6 (Statens Serum Institute, Neufeld 
antisera to group 6) was used as a positive control and Anti-Hep-A purified human IgG was 
used as a negative control. Samples were incubated for 1.5h at 37°C, fixed with 
paraformaldehyde (PFA) and analysed on a BD LSR II Flow Cytometer (BD Biosciences, 
San Jose, CA, USA). Bacterial population was gated in the Forward scatter (FSC) and 
Sideward scatter (SSC) dot plot referring to cell size and granularity. PMT voltages and 
threshold were gated on negative control bacteria. Agglutination was quantified by 
calculating the proportion of the bacterial population with altered FSC and SSC and values 
were expressed as % of agglutination, as previously described. 30, 31 All samples were 
analysed in duplicate and 30,000 events were acquired using FacsDiva Software 6.1 (BD 
Biosciences, San Jose, CA, USA). Analysis was performed using FlowJo software version 
10.0 (Tree Star Inc, San Carlos, CA, USA).
Similar assays were performed for rabbit sera with minor modifications; several serum 
dilutions were tested, samples were incubated for 1hr at 37°C then analysed on a BD 
FACSCalibur Flow Cytometer. Agglutination was quantified as above for each serum 
dilution. Agglutination was confirmed by imaging events at 60× magnification on an Amnis 
Image StreamX Imaging Flow Cytometer equipped with INSPIRE software (Amnis, EMD 
Millipore). Image analysis was performed using IDEAS software (Amnis, EMD Millipore).
Passive immunization experiments
Passive immunization was performed, as described previously. 5 C57Bl/6J (Jackson 
Laboratories, Bar Harbor, ME) mice were housed in accordance with Institutional Animal 
Care and Use Committee protocols. 5-6 weeks old adult mice were immunized 
intraperitoneally (IP) with 200μl of hyperimmune rabbit anti-pneumococcal sera. Mice were 
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inoculated intranasally (IN) 4 hours post-immunization with 10μl containing approximately 
2 × 104 CFU P1121 in PBS. At 20 hours post pneumococcal inoculation, mice were 
euthanized, the trachea cannulated, and 200μl of PBS instilled and lavage fluid was collected 
from the nares for quantitative culture. Lavage fluid was vortexed vigorously prior to plating 
to ensure any bacterial aggregates were dissociated. We have previously used quantification 
by a DNA-based assay to confirm that agglutination was not confounding colony counting.5 
The limit of detection was 2 CFU/animal.
Statistics
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc, La 
Jolla, CA). For comparison of murine data Mann-Whitney test was performed when two 
groups were compared and Kruskal-Wallis test with Dunn's post-test was performed when 
three or more groups were compared. Where appropriate, data were logarithmically 
transformed to obtain data with a normal distribution. Unpaired t tests were used to compare 
levels of purified CPS between groups. Multiple comparisons were made within carriage+ 
and carriage− groups using one-way ANOVA with Bonferroni post-test. Sera IgG levels 
correlated with mucosal IgG using Spearman's correlation, linear regression. Differences 
were considered significant at P≤0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Flow cytometric assay to quantify agglutination
(A) Representative dot plots from BD FACS Calibur with FSC v SSC of P1121 with 
increasing concentrations of type-specific rabbit anti-pneumococcal serum (corresponding to 
a total IgG concentration of 0, ~2.5, ~25, and ~250 micrograms/ml). Bacterial cells were 
gated to remove small debris particles. Percent agglutination is calculated by the sum of 
events in Q1, Q2 and Q3. Representative images are shown from Amnis ImageStreamX 
Imaging flow cytometer corresponding to the conditions shown above. (B) Representative 
dot plots and images from P1121 incubated with either Fab or F(ab’)2 fragments of type-
specific rabbit anti-pneumococcal IgG at 50μg/ml.
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FIGURE 2. Capsule is the major agglutinating antigen and leads to enhanced protection
(A) ELISA geometric mean titer (GMT) of rabbit antisera raised to isogenic capsular 
polysaccharide (cps) +/− strains, binding to encapsulated (P1121) or unencapsulated 
(P1121Δcps) whole cell pneumococci. Mean +/− SD, n = 2-4 per condition. (B) ELISA 
GMT of rabbit sera raised to cps+/−strains binding to type 23 purified CPS. Mean +/− SD, n 
= 3. (C) Flow cytometric agglutination assay comparing the titers at which a 3-fold increase 
in percent agglutination of pneumococci is observed with rabbit antisera raised to cps+/− 
strains. Mean +/− SD, n = 3-4 per condition. (D) Flow cytometry agglutination assay 
comparing the titers at which a 3-fold increase in percent agglutination for strains in which 
the capsule genes and type were switched is observed with rabbit antisera raised to 
encapsulated P1121 (type 23F). Mean +/− SD, n = 4-5 per condition. The baseline percent 
agglutination was calculated for each individual experiment and ranged from only 2-10%. 
(E) Passive protection experiment in mice immunized IP with rabbit serum raised to cps+/− 
strains. Four hours later, mice were given an intranasal dose of P1121 and colonization 
measured at 20 hours post-inoculation. Mean +/− SEM. Kruskal-Wallis test with Dunn's 
post-test was performed for (A), (C) and (D). Unpaired T test was performed for (B), and 
Mann-Whitney test was performed for (E). ns, non-significant, **P<0.01, and ****P<0.001
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FIGURE 3. Drop in type specific IgG levels to CPS in nasal wash following pneumococcal 
inoculation
(A, C, E, G) IgG levels to 6B CPS (B, D, F, H) and IgG levels to 23F CPS. Levels were 
measured in serum and nasal wash samples in (A-D) PCV vaccinated subjects and (E-H) 
control group using WHO standardised ELISA. Each dot represents IgG levels from a 
subject expressed in ng/ml. Levels were measured from carriage− (closed dots) and carriage
+ (open dots) subjects at the time-points indicated on the X-axis. Data are presented as GMC 
and 95% CI. Results were analysed using oneway ANOVA test and Bonferroni's multiple 
comparison tests. ***p<0.0001, **p<0.005, *p<0.01
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FIGURE 4. Sera IgG levels correlate with mucosal IgG following PCV vaccination
Correlation between IgG levels to 6B CPS measured in sera and nasal wash samples 
collected post PCV vaccination (Post-V) in carriage− (closed dots) and carriage+ (open 
dots) subjects. Spearman r= 0.59 and p<0.0001.
Mitsi et al. Page 16
Mucosal Immunol. Author manuscript; available in PMC 2017 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 5. Increased nasal antibody-mediated pneumococcal agglutination promoted by PCV 
vaccination
(A) Percentage of pneumococcal agglutination promoted by nasal wash samples from PCV 
vaccinated subjects before inoculation, carriage− (closed dots, n=20) and carriage+ subjects 
(open dots, n=5)) before (Pre-V) and after (Post-V) vaccination. Data are presented as GMC 
and 95% CI. Results were analysed using Mann-Whitney test.
(B) Correlation between IgG levels to CPS 6B Post-V in nasal washes and promoted 
pneumococcal agglutination % in carriage− (closed dots) and carriage+ (open dots) subjects. 
Spearman r= 0.60 and p=0.002.
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FIGURE 6. Nasal wash agglutination capacity does not correlate with protection from 
experimental carriage in control vaccinated subjects
(A) Percentage of pneumococcal agglutination promoted by nasal wash samples obtained 
from control group (Hep-A vaccinated) before pneumococcal inoculation, carriage− (closed 
dots, n=20) and carriage+ subjects (open dots). Data are presented as GMC and 95% CI. 
Results were analysed using Mann-Whitney test.
(B) Correlation between IgG levels to CPS 6B in nasal washes and promoted pneumococcal 
agglutination % in carriage− subjects. Spearman r= 0.06 and p=0.79.
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(C) Correlation between IgG levels to CPS 6B in nasal washes and promoted pneumococcal 
agglutination % in carriage+ subjects. Spearman r= 0.13 and p=0.56
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